{"id":"NCT01734239","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)","officialTitle":"A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-03","primaryCompletion":"2013-10-22","completion":"2013-10-22","firstPosted":"2012-11-27","resultsPosted":"2014-09-05","lastUpdate":"2018-10-30"},"enrollment":102,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumovax™ 23","otherNames":["V110"]}],"arms":[{"label":"Pneumovax™ 23: Participants Between 2 and 49 Years","type":"EXPERIMENTAL"},{"label":"Pneumovax™ 23: Participants >=50 Years","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if Pneumovax™ 23 (V110) is safe and immunogenic in participants from the Russian population who are 50 years of age and older or 2 to 49 years of age and at increased risk for pneumococcal disease","primaryOutcome":{"measure":"Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine","timeFrame":"Prevaccination and Day 28 after vaccination","effectByArm":[{"arm":"Pneumovax™ 23: Participants Between 2 and 49 Years","deltaMin":0.2,"sd":null},{"arm":"Pneumovax™ 23: Participants >=50 Years","deltaMin":0.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":13},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27149114"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":102},"commonTop":["Injection site pain"]}}